Expansion and activation of T cells in the wave bioreactor platform in chemically defined and serum free OptiPEAK T Lymphocyte media

Abstract

Background & Aim Expansion of human T cells has become a critical tool in the development of immunotherapies to treat a wide spectrum of diseases. As both autologous and allogeneic immunotherapies continue to show success in the clinic, the importance of having an optimized T cell expansion platform has been made even more apparent. Standard components used to grow these cells often include human or bovine serum which not only risk the introduction of harmful pathogens but also have significant limitations on the ability to deliver robust and consistent cell culture performance. Methods, Results & Conclusion To circumvent these issues, we have developed a chemically defined and animal-component free media, OptiPEAK T Lymphocyte, that demonstrates sufficient growth and expansion of human primary T cells in the wave bioreactor without requiring the addition of serum or serum-derived proteins. Expanded cells in OptiPEAK T Lymphocyte also exhibit a less differentiated phenotypic profile as proven by the presence of increased T memory stem cell subsets. In conclusion, T cell expansion in the wave bioreactor with OptiPEAK T Lymphocyte chemically defined media ensures robust performance without compromising safety, growth, or differentiation to deliver an effective dose for these immunotherapies. Expansion of human T cells has become a critical tool in the development of immunotherapies to treat a wide spectrum of diseases. As both autologous and allogeneic immunotherapies continue to show success in the clinic, the importance of having an optimized T cell expansion platform has been made even more apparent. Standard components used to grow these cells often include human or bovine serum which not only risk the introduction of harmful pathogens but also have significant limitations on the ability to deliver robust and consistent cell culture performance. To circumvent these issues, we have developed a chemically defined and animal-component free media, OptiPEAK T Lymphocyte, that demonstrates sufficient growth and expansion of human primary T cells in the wave bioreactor without requiring the addition of serum or serum-derived proteins. Expanded cells in OptiPEAK T Lymphocyte also exhibit a less differentiated phenotypic profile as proven by the presence of increased T memory stem cell subsets. In conclusion, T cell expansion in the wave bioreactor with OptiPEAK T Lymphocyte chemically defined media ensures robust performance without compromising safety, growth, or differentiation to deliver an effective dose for these immunotherapies.